Cost of Acute and Sequelae Care for Japanese Encephalitis Patients, Bangladesh, 2011-2021.

Bangladesh Japanese Japanese encephalitis Japanese encephalitis vaccines cost of illness encephalitis virus viruses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 22 11 2023
pubmed: 21 11 2023
entrez: 21 11 2023
Statut: ppublish

Résumé

Japanese encephalitis (JE) is associated with an immense social and economic burden. Published cost-of-illness data come primarily from decades-old studies. To determine the cost of care for patients with acute JE and initial and long-term sequelae from the societal perspective, we recruited patients with laboratory-confirmed JE from the past 10 years of JE surveillance in Bangladesh and categorized them as acute care, initial sequalae, and long-term sequelae patients. Among 157 patients, we categorized 55 as acute, 65 as initial sequelae (53 as both categories), and 90 as long-term sequelae. The average (median) societal cost of an acute JE episode was US $929 ($909), of initial sequelae US $75 ($33), and of long-term sequelae US $47 ($14). Most families perceived the effect of JE on their well-being to be extreme and had sustained debt for JE expenses. Our data about the high cost of JE can be used by decision makers in Bangladesh.

Identifiants

pubmed: 37987586
doi: 10.3201/eid2912.230594
pmc: PMC10683813
doi:

Substances chimiques

Japanese Encephalitis Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2488-2497

Subventions

Organisme : Bill & Melinda Gates Foundation
ID : INV-008523
Pays : United States

Références

Cost Eff Resour Alloc. 2005 Jan 19;3(1):1
pubmed: 15659245
Soc Sci Med. 2006 Feb;62(4):858-65
pubmed: 16099574
Vaccine. 2012 Aug 10;30(37):5569-77
pubmed: 22698453
Southeast Asian J Trop Med Public Health. 2001 Dec;32(4):682-8
pubmed: 12041539
Emerg Infect Dis. 2009 Jan;15(1):1-7
pubmed: 19116041
Vaccine. 2010 Jun 23;28(29):4593-9
pubmed: 20470803
Am J Trop Med Hyg. 2010 Feb;82(2):344-9
pubmed: 20134015
Bull World Health Organ. 2010 Aug 1;88(8):584-92
pubmed: 20680123
Bull World Health Organ. 2011 Oct 1;89(10):766-74, 774A-774E
pubmed: 22084515
Int J Infect Dis. 2020 Oct;99:69-74
pubmed: 32721530
PLoS Negl Trop Dis. 2021 Jun 21;15(6):e0009505
pubmed: 34153039
J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):405-15
pubmed: 10727474
PLoS Negl Trop Dis. 2015 Mar 20;9(3):e0003630
pubmed: 25794009
Soc Sci Med. 1997 Jun;44(12):1781-90
pubmed: 9194240
J Trop Med Hyg. 1981 Feb;84(1):41-4
pubmed: 6259374
J Trop Pediatr. 2001 Apr;47(2):98-105
pubmed: 11336143
Bull World Health Organ. 2003;81(5):334-42
pubmed: 12856051
PLoS Negl Trop Dis. 2021 Jun 11;15(6):e0009439
pubmed: 34115764
Braz J Infect Dis. 2012 Nov-Dec;16(6):564-73
pubmed: 23141974
PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2383
pubmed: 24069467

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH